转移性去势初治前列腺癌的新型治疗选择:如何选择治疗模式
综述回顾2015年以来转移性去势初治前列腺癌(mCNPC)的治疗进展,指出ADT联合多西他赛或阿比特龙可显著改善总生存,但缺乏早期疗效和风险分层生物标志物,难以个体化选择。低瘤负荷患者中ADT联合原发灶放疗或阿比特龙均显示生存获益,阿帕他胺或恩扎卢胺联合ADT亦显示生存获益,转移范围可能成为治疗选择的关键因素。
要点
- ADT联合多西他赛或阿比特龙可显著改善mCNPC总生存。
- 低瘤负荷患者中ADT联合原发灶放疗或阿比特龙均显示生存获益。
- 阿帕他胺或恩扎卢胺联合ADT亦显示生存获益,转移范围可能指导治疗选择。
核心结论
- ADT联合多西他赛、阿比特龙、阿帕他胺或恩扎卢胺均可改善mCNPC生存,转移范围可能成为治疗选择的关键因素。
研究设计与样本
- 综述文章,汇总2015年以来mCNPC治疗相关试验数据以提供治疗选择指导。
主要发现
- ADT联合多西他赛或阿比特龙可显著改善mCNPC总生存。
- 低瘤负荷患者中ADT联合原发灶放疗或阿比特龙均显示生存获益。
- 阿帕他胺或恩扎卢胺联合ADT亦显示生存获益。
- 缺乏早期疗效反应和风险分层生物标志物,限制个体化医疗。
- 新影像技术早期检出转移使临床试验结果在日常实践中应用更具挑战。
临床怎么用
- 转移范围(瘤负荷)可能作为mCNPC治疗选择的重要参考因素。
局限性
- 缺乏早期疗效反应和风险分层生物标志物,难以个体化选择治疗。
- 新影像技术早期检出转移使临床试验结果在日常实践中应用更具挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Androgen-deprivation therapy (ADT) has been the mainstay of treatment of metastatic prostate cancer since the first report of its hormonal dependence in the 1940s. Since 2015, the addition of docetaxel and the addition of abiraterone to ADT have conferred substantial overall survival benefit in men with metastatic castration-naïve prostate cancer (mCNPC). The shift of these treatment options for metastatic prostate cancer from the castration-resistant setting to the castration-naïve setting has led to new challenges in the management of this disease. It remains to be determined which patients may benefit most from either early concomitant docetaxel or from abiraterone with ADT, since biomarkers for early therapy response and risk stratification are currently lacking. Therefore, the ability to personalize medicine is hampered. Furthermore, the earlier detection of metastatic prostate cancer by using new imaging modalities makes the application of clinical trial results in daily practice increasingly challenging. Recently, both local radiotherapy to the primary tumor combined with ADT and abiraterone combined with ADT showed a survival benefit in low-volume disease patients. The latest data also demonstrated a survival benefit with the addition of apalutamide or enzalutamide to ADT. The extent of metastatic disease may become one of the most important factors to determine treatment choice. In this review article, we summarize trial data to provide guidance for treatment selection in metastatic castration-naïve prostate cancer.
引用
- Belderbos BPS, de Wit R, Lolkema MPJ, et al. Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose? Ann Oncol. 2019. PMID: 31340031. doi:10.1093/annonc/mdz210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。